Objectives: Previous estimates of the prevalence of anxiety disorders in late life vary greatly due to the lack of reliable diagnostic tools. This MentDis_ICF65+ study assessed 12-month prevalence rates of anxiety disorders and age- and gender-related differences in comorbidities, as well as impact on quality of life.
Design: The study used a cross-sectional multicenter survey.
Participants: The study sample comprised 3,142 men and women aged 65 to 84 years, living in five European countries and Israel.
Measurements: Anxiety disorders were assessed using computer-assisted face-to-face interviews with an age-appropriate diagnostic interview (CIDI65+).
Results: The prevalence of anxiety disorders was 17.2%. Agoraphobia was the most frequent disorder (4.9%), followed by panic disorder (3.8%), animal phobia (3.5%), general anxiety disorder (3.1%), post-traumatic stress disorder (1.4%), social phobia (1.3%), and obsessive-compulsive disorder (0.8%). The prevalence rate of any anxiety disorder dropped by 40% to 47% in adults aged 75-84 years compared with those aged 65-74 years. Women were twice as likely to present with agoraphobia or general anxiety disorder as men. Only panic disorder and phobia were associated with comorbid major depression. The negative relationship with quality of life was limited to agoraphobia and generalized anxiety disorder.
Conclusions: The age-appropriate CIDI65+ led to higher prevalence rates of anxiety disorders in the elderly, yet to weaker associations with comorbidities and impaired quality of life compared with previous studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jagp.2017.08.015 | DOI Listing |
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Participant dropout from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. This analysis aims to identify the baseline characteristics of participants who discontinued during the blinded phase of one of the first and largest preclinical AD trial completed to date, the Anti-Amyloid treatment in Asymptomatic AD (A4) Study.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Ibadan, Ibadan, Oyo, Nigeria.
Background: Aluminium chloride, an environmental toxicant induces neurotoxicity by increasing anxiety, causing cognitive deficit and memory impairment due to its effects on the hippocampus. Omega-3 oil has been shown to improve cognition in neurologic disorders.
Method: Forty adult female rats were divided into 4 groups (n = 10).
Alzheimers Dement
December 2024
University of Buenos Aires, Buenos Aires, Argentina.
Background: Increasing evidence points to the possible risk roles of psychosocial factors (lack of education, active social participation, physical exercise and mentally stimulating activity, economic instability, traumatic life events) in the pathogenic process and clinical manifestation of dementia disorders. In recent years in our country, in the context of a complex inflationary process, there has been an increase in all indicators of vulnerability and poverty, exceeding 40% of the population below the poverty line in 2023 and around 9% below the indigence line.
Method: In the context of International Alzheimer's Day, the Alzheimer's Disease Awareness Week was held at the Hospital de Clínicas of Buenos Aires.
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Amyloid imaging biomarkers serve an increasingly important role in diagnosing Alzheimer's disease and determining eligibility for treatment with new disease-modifying therapies. Yet, psychological and behavioral reactions to receiving a biomarker informed diagnosis remain relatively unstudied, especially in diverse and underserved populations where the burden of disease is high and resources for support are often insufficient. We developed the Patient And family member Reactions to biomarker-informed ADRD DiagnosEs (PARADE) Study to address two key gaps in our understanding: 1) the range and trajectory of psychological and behavioral responses to a biomarker informed diagnosis and 2) the support needs of these individuals and their families.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: It has been validated that dementia can be alleviated by talk therapy. While general large language models (LLMs) have the potential for talk therapy and dementia treatment, customized LLMs resembling a mental-health therapist can be more professional and powerful. We introduced an LLM solution designed for tailored mental health support for future dementia care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!